Hear more from our interview with Dr. Rosenthal, where she talks about the best career advice she’s ever received and the best (and worst) parts of her day.
Recent Articles
Another IDH Inhibitor Option for Acute Myeloid Leukemia?
The IDH1 inhibitor olutasidenib, as a single agent and in combination with azacitidine, demonstrated “favorable safety and clinical activity” in patients with IDH1-mutated acute...
Romiplostim and Eltrombopag Beat Rituximab for Secondline Chronic Immune Thrombocytopenia Treatment
After frontline treatment with corticosteroids fails to elicit a response in patients with chronic immune thrombocytopenia (cITP), the choice between rituximab or thrombopoietin receptor...
Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL
The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of chronic lymphocytic leukemia (CLL) has reshaped the treatment paradigm...
Registry Analysis Finds Off-Label Rituximab Improves Outcomes in Patients With iTTP
For patients with de novo immune thrombocytopenic purpura (iTTP), adding rituximab to corticosteroids appears to delay, but not prevent, relapse, according to results from...
Are Clinical Trials Exclusion Criteria for Patients With AML Too Strict?
In a study presented at the 2019 ASH Annual Meeting, researchers found that certain comorbidities in patients with acute myeloid leukemia (AML) do not...
Current Issue
December 2019, Volume 5, Issue 15
This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.
